Feb 28 |
Editas spikes as Vertex Pharma deal boosts Q4 topline
|
Feb 28 |
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
|
Feb 28 |
Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials
|
Feb 28 |
Editas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32M
|
Feb 28 |
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
|
Feb 27 |
Editas Medicine Q4 2023 Earnings Preview
|
Feb 21 |
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
|
Feb 19 |
Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade
|
Feb 14 |
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
|
Feb 13 |
Editas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)
|